Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease

References

• Bhatt DL, Eagle KA, Ohman EM, et al. ; REACH registry investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350–1357.
   PubMed Web of Science ®Google Scholar
• Miao B, Hernandez AV, Alberts MJ, et al. Incidence and predictors of major adverse cardiovascular events in patients with established atherosclerotic disease or multiple risk factors. J Am Heart Assoc. 2020;9(2):e014402.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–1330.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–1717.
   PubMed Web of Science ®Google Scholar
• Leeper NK, Ting W, Kharat A, et al. Incidence of major adverse cardiovascular and/or limb events among patients using aspirin for secondary prevention. Adv Card Res. 2020;3(2):266–274.
   Google Scholar
• Berger A, Simpson A, Bhagnani T, et al. Incidence and cost of major adverse cardiovascular events and major adverse limb events in patients with chronic coronary artery disease or peripheral artery disease. Am J Cardiol. 2019;123(12):1893–1899.
   PubMed Web of Science ®Google Scholar
• Berger A, Simpson A, Leeper NJ, et al. Real-world predictors of major adverse cardiovascular events and major adverse limb events among patients with chronic coronary artery disease and/or peripheral arterial disease. Adv Ther. 2020;37(1):240–252.
   PubMed Web of Science ®Google Scholar
• Visseren FLJ, Mach F, Smulders YM, et al. ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes – 2021. Diabetes Care. 2021;44(Suppl 1):S125–S150.
   PubMedGoogle Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Wu O, Briere JB, et al. Antithrombotic treatments in patients with chronic coronary artery disease or peripheral artery disease: a systematic review of randomised controlled trials. Cardiovasc Ther. 2020; 2020:3057168.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
   PubMed Web of Science ®Google Scholar
• Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123(23):2736–2747.
   PubMed Web of Science ®Google Scholar
• Bergmark BA, Kamphuisen PW, Wiviott SD, et al. Comparison of events across bleeding scales in the ENGAGE AF-TIMI 48 trial. Circulation. 2019;140(22):1792–1801.
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691.
   PubMed Web of Science ®Google Scholar
• Berger PB, Bhatt DL, Fuster V, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease. Results from the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial. Circulation. 2010;121(23):2575–2583.
   PubMedGoogle Scholar
• Eikelboom JW, Bosch JJ, Connolly SJ, et al. Major bleeding in patients with coronary or peripheral artery disease treated with rivaroxaban plus aspirin. J Am Coll Cardiol. 2019;74(12):1519–1528.
   PubMed Web of Science ®Google Scholar
• Berger JS, Bhatt DL, Cannon CP, et al. The relative efficacy and safety of clopidogrel in women and men. A sex-specific collaborative meta-analysis. J Am Coll Cardiol. 2009;54(21):1935–1945.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Bhatt DL, Fox KAA, et al. Mortality benefit of rivaroxaban plus aspirin in patients with chronic coronary or peripheral artery disease. J Am Coll Cardiol. 2021;78(1):14–23.
   PubMed Web of Science ®Google Scholar
• Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219–229.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994–2004.
   PubMed Web of Science ®Google Scholar
• Belch JJ, Dormandy J, CASPAR Writing Committee, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52(4):825–833, 833.e1-2.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 2011;14(4):417–428.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947.
   PubMed Web of Science ®Google Scholar